Federal Register of Legislation - Australian Government

Primary content

Poisons Standard Amendment No. 1 of 2013

Authoritative Version
  • - F2013L00527
  • No longer in force
No. 1 of 2013 Standards/Other as made
This instrument amends the Poisons Standard 2012.
Administered by: Health
Registered 21 Mar 2013
Tabling HistoryDate
Tabled HR14-May-2013
Tabled Senate14-May-2013
Date of repeal 02 May 2013
Repealed by Division 1 of Part 5A of the Legislative Instruments Act 2003

 

 

 

H&A TGA vert blackBOLD 70

 

 

 

POISONS STANDARD AMENDMENT No. 1 OF 2013

 

I, ANTHONY GILL, a delegate of the Secretary to the Department of Health and Ageing for the purposes of paragraph 52D(2)(a) of the Therapeutic Goods Act 1989 (the Act) and acting in accordance with the Secretary’s power under that paragraph of the Act, hereby amend the Poisons Standard 2012 in the manner set out in Schedule 1.

 

The amendments to the Poisons Standard 2012 as set out in Schedule 1 commence on 1 May 2013.

 

 

(Signed by)

 

ANTHONY GILL

Delegate of the Secretary to the Department of Health and Ageing

 

 

Dated this 14th            day of March 2013

 


 

Schedule 1-Amendments to the Poisons Standard 2012

 

 

 

STANDARD

FOR THE

UNIFORM SCHEDULING

OF

MEDICINES AND POISONS

 

No. 3

 

 

 

AMENDMENT No. 5

 

Effective Date – 1 May 2013


ISBN: 978-1-74241-893-3

 

© Commonwealth of Australia 2013

 

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or via e-mail to copyright@health.gov.au.

 

Published by the Australian Government.

 

Publications approval number: 10085

 

 

 

 

 

 

 

The amendments listed in this document are a result of decisions made by a delegate of the Department of Health and Ageing in November 2012 and in February and March 2013.  The basis of these amendments can be found in the ‘Reasons for scheduling delegate’s final decisions’, which can be accessed from the TGA website at www.tga.gov.au/industry/scheduling-decisions.htm.

 

Further inquiries should be directed to:

 

The Secretary

Medicines and Poisons Scheduling Secretariat (MDP88)

Office of Health Protection

Department of Health and Ageing

GPO Box 9848

CANBERRA  ACT  2601

 

or by email:  SMP@health.gov.au

 

Media Liaison Unit

Australian Government Department of Health and Ageing


 


Amendments to the Standard for the Uniform Scheduling of Medicines and Poisons

The Secretary to the Department of Health and Ageing directs that the amendments below be applied to the Standard for the Uniform Scheduling of Medicines and Poisons No. 3 (SUSMP 3) and recommends that these amendments be adopted by the states and territories with effect from 1 May 2013. 

 

PART 4 – THE SCHEDULES

 

SCHEDULE 2 – AMENDMENT

 

DICLOFENAC – Amend entry to read:

 

DICLOFENAC when:

 

(a)                in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;

 

(b)                in preparations for dermal use containing 4 per cent or less of diclofenac except in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or

 

(c)                in transdermal preparations for topical use containing 140 mg or less of diclofenac.

 

SCHEDULE 3 – NEW ENTRY

 

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose. 

 

SCHEDULE 4 – NEW ENTRIES

 

ALOGLIPTIN.

 

BESIFLOXACIN HYDROCHLORIDE.

 

CANAGLIFLOZIN.

 

CROFELEMER.

 

DIMETHYL FUMARATE.

 

ENOBOSARM.

 

IVACAFTOR.

MICAFUNGIN.

 

OLODATEROL.

 

PASIREOTIDE.

 

PASIREOTIDE DIASPARTATE.

 

PRUCALOPRIDE.

 

RETAPAMULIN.

 

RETIGABINE.

 

#SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

 

TERIFLUNOMIDE.

 

TILDIPIROSIN.

 

VILANTEROL.

 

VILANTEROL TRIFENATATE.

 

SCHEDULE 4 – AMENDMENT

 

VITAMIN D – Amend entry to read:

 

VITAMIN D for human internal therapeutic use except:

 

(a)                in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or

 

(b)        when included in Schedule 3.

 

SCHEDULE 5 – NEW ENTRY

 

CYANTRANILIPROLE.

 

SCHEDULE 6 – NEW ENTRY

 

THYMOL when packed and labelled for the control of Varroa mites in bee hives.


 

PART 5 – THE APPENDICES

 

Appendix C – New entries

 

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

 

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations manufactured for and supplied solely by registered dental practitioners as part of their dental practice.

 

Appendix D, PARAGRAPH 5 – New entrY

 

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.

 

APPENDIX F, PART 3 – NEW ENTRY

 

Poison                                                             Warning statement

Teriflunomide                                                 7, 62, 87

 

APPENDIX K – NEW ENTRY

 

RETIGABINE

 

APPENDIX L – NEW ENTRY

 

Column 1                                                       Column 2

Substance                                                       Warning statement

Teriflunomide.                                                7, 62 and 87


 

EDITORIAL AMENDMENTS AND ERRATA

 

PART 4 – THE SCHEDULES

 

SCHEDULE 2 - AMENDMENT

 

FEXOFENADINE – Amend entry to read:

 

FEXOFENADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 

(a)                in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and

 

(b)                labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

 

SCHEDULE 4 - AMENDMENTS

 

FEXOFENADINE – Amend entry to read:

 

FEXOFENADINE except:

 

(a)        when included in Schedule 2; or

 

(b)        in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

 

(i)        in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and

 

(ii)       labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

 

FORMOTEROL – Amend entry to read:

 

EFORMOTEROL.

 


 

PART 5 – THE APPENDICES

 

APPENDIX L – amendments

 

Column 1                                                       Column 2

Substance                                                       Warning statement

 

Acitretin – Amend entry to read:

Acitretin:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Adapalene – Amend entry to read:

Adapalene:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Ambrisentan – Amend entry to read:

Ambrisentan                                                    7, 62 and 76

 

Bexarotene – Amend entry to read:

Bexarotene:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Bosentan – Amend entry to read:

Bosentan                                                         7, 62 and 76

 

Etretinate – Amend entry to read:

Etretinate:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 


 

Appendix L – Amendments (continued)

Column 1                                                       Column 2

Substance                                                       Warning statement

Isotretinoin – Amend entry to read:

Isotretinoin:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Leflunomide – Amend entry to read:

Leflunomide                                                   7, 62 and 76

 

Lenalidomide – Amend entry to read:

Lenalidomide:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Sitaxentan – Amend entry to read:

Sitaxentan                                                       7, 62 and 76

 

Thalidomide – Amend entry to read:

Thalidomide:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77

 

Tretinoin – Amend entry to read:

Tretinoin:

(i)                 for oral use.                                   7, 62 and 76

(ii)               for topical use.                              62 and 77